Even as India’s largest drug maker, Ranbaxy, is confident of launching its first “new drug” by January 2012 to combat malaria in the country, the global euphoria the potential drug had generated in the initial stages of its research seems missing.
Health experts attribute this to the absence of international approval for the drug. About 90 per cent of malaria infections are reported from sub-Saharan Africa. Other tropical regions, including India, account for the rest.